MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 206441 | Name: Etripamil
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Etripamil is a calcium channel blocker. Calcium channel blockers (CCB), calcium channel antagonists or calcium antagonists are several medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension.

Chemical Structure

Etripamil
Etripamil
CAS#1593673-23-4 (free base)

Theoretical Analysis

MedKoo Cat#: 206441

Name: Etripamil

CAS#: 1593673-23-4 (free base)

Chemical Formula: C27H36N2O4

Exact Mass: 452.2675

Molecular Weight: 452.60

Elemental Analysis: C, 71.65; H, 8.02; N, 6.19; O, 14.14

Price and Availability

Size Price Availability Quantity
50mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
200mg USD 2,650.00 2 Weeks
500mg USD 5,250.00 2 Weeks
1g USD 7,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
2560549-35-9 (HCl) 1593673-23-4 (free base)
Synonym
(-)-MSP-2017; MSP-2017; MSP 2017; MSP2017; MSP-2017A; MSP-2017B; Etripamil
IUPAC/Chemical Name
methyl (S)-3-(2-((4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl)(methyl)amino)ethyl)benzoate
InChi Key
VAZNEHLGJGSQEL-MHZLTWQESA-N
InChi Code
InChI=1S/C27H36N2O4/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t27-/m0/s1
SMILES Code
O=C(OC)C1=CC=CC(CCN(CCC[C@](C2=CC=C(OC)C(OC)=C2)(C#N)C(C)C)C)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
L-type calcium channel
In vitro activity:
TBD
In vivo activity:
This phase 2 study was performed during electrophysiological testing in patients with previously documented SVT who were induced into SVT prior to undergoing a catheter ablation. Patients in sustained SVT for 5 min received either placebo or 1 of 4 doses of active compound. The primary endpoint was the SVT conversion rate within 15 min of study drug administration. Secondary endpoints included time to conversion and adverse events. One hundred four patients were dosed. Conversion rates from SVT to sinus rhythm were between 65% and 95% in the etripamil nasal spray groups and 35% in the placebo group; the differences were statistically significant (Pearson chi-square test) in the 3 highest active compound dose groups versus placebo. In patients who converted, the median time to conversion with etripamil was <3 min. Adverse events were mostly related to the intranasal route of administration or local irritation. Reductions in blood pressure occurred predominantly in the highest etripamil dose. Etripamil nasal spray rapidly terminated induced SVT with a high conversion rate. The safety and efficacy results of this study provide guidance for etripamil dose selection for future studies involving self-administration of this new intranasal calcium-channel blocker in a real-world setting for the termination of SVT. Reference: Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondésert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082. PMID: 30049309.
Solvent mg/mL mM
Solubility
Ethanol 120.0 265.13
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 452.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondésert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082. PMID: 30049309.
In vitro protocol:
TBD
In vivo protocol:
Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondésert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082. PMID: 30049309.
1: Huston J, Genovese A, Ashchi A, DeLuca A, Wiener J, Deeb E, Deeb A, Goldfaden RF. Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia. Am J Cardiovasc Drugs. 2023 Sep;23(5):471-475. doi: 10.1007/s40256-023-00589-2. Epub 2023 Jun 6. Erratum in: Am J Cardiovasc Drugs. 2023 Jul 21;: PMID: 37278974. 2: Raja JM, Cave B, Jefferies JL, Khouzam RN. Etripamil: Intranasal Calcium Channel Blocker: A Novel Noninvasive Modality in the Treatment of Paroxysmal Supraventricular Tachycardia. Curr Probl Cardiol. 2021 Mar;46(3):100430. doi: 10.1016/j.cpcardiol.2019.05.003. Epub 2019 Jun 22. PMID: 31279494. 3: Kashou AH, Noseworthy PA. Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT). Expert Opin Investig Drugs. 2020 Jan;29(1):1-4. doi: 10.1080/13543784.2020.1703180. Epub 2019 Dec 12. PMID: 31825681. 4: Chu GS, Gupta D. Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia. Heart Int. 2021 Jul 15;15(1):2-6. doi: 10.17925/HI.2021.15.1.2. PMID: 36277324; PMCID: PMC9524608. 5: Faisaluddin M, Ashish K, Hajra A, Mondal S, Bandyopadhyay D. Etripamil: Self- management of supraventricular tachycardia is not far away? Int J Cardiol Heart Vasc. 2019 Jan 4;22:82-83. doi: 10.1016/j.ijcha.2018.12.007. PMID: 30627628; PMCID: PMC6321861. 6: Weintraub S, Frishman WH. A Novel Calcium Channel Blocker: Etripamil: What is the Future of Intranasal Drug Delivery in the Treatment of Cardiac Arrhythmias? Cardiol Rev. 2021 Sep-Oct 01;29(5):253-258. doi: 10.1097/CRD.0000000000000362. PMID: 33060411. 7: Ip JE, Coutu B, Bennett MT, Pandey AS, Stambler BS, Sager P, Chen M, Shardonofsky S, Plat F, Camm AJ. Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study. J Am Heart Assoc. 2023 Oct 3;12(19):e028227. doi: 10.1161/JAHA.122.028227. Epub 2023 Sep 27. PMID: 37753718. 8: Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondésert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082. PMID: 30049309. 9: Huston J, Genovese A, Ashchi A, DeLuca A, Wiener J, Deeb E, Deeb A, Goldfaden RF. Correction to: Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia. Am J Cardiovasc Drugs. 2023 Nov;23(6):735-736. doi: 10.1007/s40256-023-00595-4. Erratum for: Am J Cardiovasc Drugs. 2023 Sep;23(5):471-475. PMID: 37477826. 10: Stambler BS, Camm AJ, Alings M, Dorian P, Heidbuchel H, Houtgraaf J, Kowey PR, Merino JL, Mondésert B, Piccini JP, Pokorney SD, Sager PT, Verma A, Wharton JM, Bharucha DB, Plat F, Shardonofsky S, Chen M, Ip JE; RAPID Investigators. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet. 2023 Jul 8;402(10396):118-128. doi: 10.1016/S0140-6736(23)00776-6. Epub 2023 Jun 15. PMID: 37331368. 11: Stambler BS, Plat F, Sager PT, Shardonofsky S, Wight D, Potvin D, Pandey AS, Ip JE, Coutu B, Mondésert B, Sterns LD, Bennett M, Anderson JL, Damle R, Haberman R, Camm AJ. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301). Circ Arrhythm Electrophysiol. 2022 Dec;15(12):e010915. doi: 10.1161/CIRCEP.122.010915. Epub 2022 Nov 28. PMID: 36441560; PMCID: PMC9760458. 12: Huynh K. RAPID return to sinus rhythm after SVT using intranasal etripamil. Nat Rev Cardiol. 2023 Sep;20(9):580. doi: 10.1038/s41569-023-00908-9. PMID: 37400625. 13: Stambler BS, Plat F, Sager PT, Lubkov V, Shardonofsky S, Wight D, Chen M, Camm AJ. Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia. Am Heart J. 2022 Nov;253:20-29. doi: 10.1016/j.ahj.2022.06.005. Epub 2022 Jun 18. PMID: 35728658. 14: Abuelazm M, Kambalapalli S, Saleh O, Elzeftawy MA, Albakri K, Gowaily I, Abdelazeem B. The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs. 2023 Jul;23(4):379-391. doi: 10.1007/s40256-023-00592-7. Epub 2023 Jun 23. PMID: 37351813; PMCID: PMC10328856. 15: Choe WC, Sundaram S, Boorman C, Mullins N, Shamszad P, Plat F. High-density mapping of the slow pathway in a patient with atrioventricular nodal reentry given intranasal Etripamil during the NODE-1 study. HeartRhythm Case Rep. 2017 Jul 27;3(10):479-482. doi: 10.1016/j.hrcr.2017.07.011. PMID: 29062702; PMCID: PMC5643855.

View History

Xenthiorate

Xenthiorate